Michael Rosenblatt

Michael A. Rosenblatt was the founder of Theracrine, Inc., founded in 2006, and Radius Health, Inc., founded in 2003 where the title held was Director.
Current jobs include Executive Chairman at Perspectum Ltd. starting in 2026; Director at Ferring Pharmaceuticals, Inc. since 2016; Director at Cygnal Therapeutics, Inc. since 2016; Director at Perspectum Group Ltd. since 2022; Advisor at PureTech Health LLC; and Senior Advisor at Flagship Pioneering, Inc. since 2016.
Former jobs include Non-Executive Director at Shire Plc from 2008 to 2009; Director at ProScript, Inc.; Director at Project HOPE-The-People-To-People Health Foundation, Inc.; Director at Harvard Mit Health Sciences & Technology in 1998; Independent Director at Axcella Health, Inc. from 2022 to 2023; Independent Director at Rubius Therapeutics, Inc. from 2014 to 2023; Non-Executive Director at PYC Therapeutics Ltd. from 2021 to 2025; Director at Ohana Biosciences, Inc.; Director at Cobalt Biomedicine, Inc.; Independent Director at Azenta, Inc. from 2018 to 2025; Chief Medical Officer & Executive Vice President at Merck & Co., Inc. from 1984 to 2016; Chief Medical Officer at Schering-Plough Corp.; Principal at The General Hospital Corp.
from 1981 to 1984; Senior Vice President-Academic Programs at CareGroup, Inc. in 2000; President at Beth Israel Deaconess Medical Center, Inc. from 1996 to 2003; Member-Scientific Counselors Board at National Institute of Diabetes & Digestive & Kidney Diseases; Senior Vice President-Research at Merck Research Laboratories Massachusetts LLC; Professor at Harvard Medical School; Senior Vice President-Research at Merck Sharp & Dohme Corp.
in 1992; Professor at Molecular Medicine LLC; and Dean at Tufts University School of Medicine.
Education includes undergraduate degree from The Trustees of Columbia University in The City of New York and doctorate from Harvard Medical School.